X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (401) 401
dihydropyrimidine dehydrogenase-deficiency (200) 200
5-fluorouracil (199) 199
dihydropyrimidine dehydrogenase (191) 191
oncology (188) 188
female (181) 181
index medicus (180) 180
male (166) 166
fluorouracil (160) 160
chemotherapy (157) 157
pharmacology & pharmacy (157) 157
fluorouracil - adverse effects (150) 150
toxicity (141) 141
middle aged (137) 137
pharmacogenetics (127) 127
dihydrouracil dehydrogenase - genetics (122) 122
antimetabolites, antineoplastic - adverse effects (118) 118
cancer (118) 118
aged (112) 112
capecitabine (110) 110
adult (98) 98
dihydropyrimidine dehydrogenase deficiency (95) 95
fluorouracil - therapeutic use (93) 93
neoplasms - drug therapy (82) 82
colorectal neoplasms - drug therapy (76) 76
colorectal cancer (74) 74
dpd deficiency (73) 73
genotype (73) 73
antimetabolites, antineoplastic - therapeutic use (72) 72
fluorouracil - administration & dosage (65) 65
mutation (62) 62
colorectal-cancer (58) 58
pharmacokinetics (58) 58
dihydrouracil dehydrogenase - metabolism (57) 57
fluorouracil - pharmacokinetics (56) 56
gene (56) 56
research (54) 54
dpyd (53) 53
medicine & public health (51) 51
animals (50) 50
deoxycytidine - analogs & derivatives (50) 50
dihydrouracil dehydrogenase (50) 50
care and treatment (49) 49
cancer-patients (48) 48
enzymes (48) 48
fluorouracil - analogs & derivatives (48) 48
uracil (46) 46
5-fluorouracil toxicity (44) 44
aged, 80 and over (44) 44
genetic aspects (44) 44
antimetabolites, antineoplastic - pharmacokinetics (42) 42
deficiency (42) 42
antineoplastic agents - therapeutic use (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
thymidylate synthase (41) 41
advanced colorectal-cancer (39) 39
population (38) 38
phenotype (37) 37
polymorphism, genetic (37) 37
uracil - analogs & derivatives (37) 37
antimetabolites, antineoplastic - administration & dosage (36) 36
deoxycytidine - adverse effects (36) 36
antineoplastic agents - adverse effects (35) 35
identification (35) 35
dihydropyrimidine dehydrogenase gene (34) 34
drug therapy (34) 34
fluoropyrimidines (34) 34
pharmacogenomics (34) 34
risk factors (34) 34
treatment outcome (34) 34
genetics & heredity (33) 33
neoplasms - genetics (33) 33
dihydropyrimidine dehydrogenase-activity (32) 32
ivs14+1g-greater-than-a mutation (32) 32
pharmacology/toxicology (32) 32
polymorphism (32) 32
biochemistry & molecular biology (31) 31
analysis (30) 30
health aspects (30) 30
metastatic colorectal-cancer (30) 30
uracil - blood (30) 30
colorectal neoplasms - genetics (29) 29
dihydropyrimidine dehydrogenase deficiency - genetics (29) 29
cell lung-cancer (28) 28
pharmacology (28) 28
cancer research (27) 27
fluorouracil - metabolism (27) 27
metabolism (27) 27
polymorphism, single nucleotide (27) 27
single nucleotide polymorphisms (27) 27
5-fu (26) 26
patients (26) 26
acute lymphoblastic-leukemia (24) 24
dihydropyrimidine dehydrogenase deficiency - diagnosis (24) 24
fluorouracil - pharmacology (24) 24
internal medicine (24) 24
mononuclear-cells (24) 24
1st-line treatment (23) 23
diagnosis (23) 23
dose-response relationship, drug (23) 23
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (472) 472
French (19) 19
Japanese (17) 17
Spanish (5) 5
German (3) 3
Dutch (2) 2
Polish (2) 2
Chinese (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cancer, ISSN 0020-7136, 01/2018, Volume 142, Issue 2, p. 424
Fluoropyrimidines are frequently used anti-cancer drugs. It is known that patients with reduced activity of dihydropyrimidine dehydrogenase (DPD), the key... 
Genetic Testing | Prognosis | Capecitabine | Humans | Middle Aged | Antimetabolites, Antineoplastic | Female | Genotype | Dihydropyrimidine Dehydrogenase Deficiency | Dihydrouracil Dehydrogenase (NADP)
Journal Article
Journal Article
Journal Article
Autopsy & case reports, ISSN 2236-1960, 10/2018, Volume 8, Issue 4, p. e2018049
5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variety of cancers. Dihydropyrimidine dehydrogenase (DPD)... 
Genetic Testing; Fluorouracil | Dihydropyrimidine Dehydrogenase Deficiency | Drug-Related Side Effects and Adverse Reactions | Pancytopenia
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2004, Volume 10, Issue 8, pp. 2652 - 2658
Journal Article
Journal Article
International Journal of Surgery Case Reports, ISSN 2210-2612, 2019, Volume 56, pp. 55 - 58
5-Fluorouracil (5-FU) is widely used for cancer treatment. The reduced activity of dihydropyrimidine dehydrogenase (DPD), the key enzyme in 5-FU inactivation,... 
Cytomegalovirus | Case report | 5-Fluorouracil | DPD deficiency
Journal Article
BULLETIN DU CANCER, ISSN 0007-4551, 09/2019, Volume 106, Issue 9, pp. 759 - 775
Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of early severe toxicities induced by fluoropyrimidines (FP). The French Group of Clinical... 
III COLON-CANCER | LEUCOVORIN | Toxicity | GENOTYPE | Dihydropyrimidine dehydrogenase | SEVERE TOXICITY | FLUOROURACIL | Surveys | CAPECITABINE | Screening | THERAPY | ONCOLOGY | DPD | Fluoropyrimidine
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.